Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biopharmaceutical company Imugene (ASX:IMU) is on track to start Phase 1 clinical trials for its cancer treatment
  • The CF33 oncolytic virus works to treat cancer by infecting and killing tumour cells while leaving healthy cells unharmed
  • Two batches the cancer treatment were successfully produced to clinical grade GMP, paving the way for Phase 1 trials in 2020
  • There are two constructs of the virus, CheckVacc and Vaxinia, which will be tested in separate trials
  • Imugene shares are down 8.77 per cent, trading for 5.2 cents apiece

Imugene Limited (ASX:IMU) is on track to start Phase 1 clinical trials for its CF33 oncolytic virus technology in 2020.

The Australian-based company specialises in immune-based cancer treatments, developed at the City of Hope Center for Biomedicine and Genetics in California.

Imugene is on track to undertake Phase 1 clinical trials after two batches of the cancer treatment were successfully produced to clinical grade GMP.

The CF33 oncolytic virus is produced in two different constructs: the CheckVacc which is “armed” with an immune checkpoint inhibitor inserted in the virus and the Vaxinia which is “unarmed.”

The company plans to conduct a separate Phase 1 trial for the different constructs at some stage in 2020.

The CF33 oncolytic virus works to treat cancer by infecting tumour cells, before multiplying and ultimately killing them. Pre-clinical trials have shown it is effective on both primary, metastatic and recurring tumours while leaving healthy cells unharmed.

Pre-clinical trials have also shown the CF33 virus technology to effectively shrink tumours at an extremely low dose.

Imugene shares are down 8.77 per cent, trading for 5.2 cents a share at 4:10pm.

IMU by the numbers
More From The Market Herald
Paradigm Biopharmaceuticals (ASX:PAR) - CEO, Marco Polizzi

" Paradigm Biopharmaceuticals (ASX:PAR) enters trading halt amid cap raise

Paradigm Biopharmaceuticals (ASX:PAR) has entered into a trading halt ahead of a capital raise.
HITIQ (ASX:HIQ) - CEO, Mike Vegar

" HITIQ (ASX:HIQ) secures third Australian innovation patent

HITIQ (ASX:HIQ) has secured a third Australian innovation patent related to its virtual reality (VR) concussion…

" Medlab Clinical (ASX:MDC) sees depression patent accepted in Europe

Medlab Clinical's (ASX:MDC) patent for depression is formally accepted by the European Patent Office.
The Market Herald Video

" Patrys (ASX:PAB) confirms PAT-DX1 improves efficacy of radiation therapy

Patrys (ASX:PAB) has released pre-clinical data for an animal study of its lead PAT-DX1 product showing…